The estimated Net Worth of Enterprise Associates 12, L... is at least $7.83 million dollars as of 26 November 2019. Enterprise L owns over 1,283,919 units of Zosano Pharma Corp stock worth over $2,391,587 and over the last 8 years Enterprise sold ZSAN stock worth over $5,433,629.
Enterprise has made over 3 trades of the Zosano Pharma Corp stock since 2017, according to the Form 4 filled with the SEC. Most recently Enterprise sold 1,283,919 units of ZSAN stock worth $3,222,637 on 26 November 2019.
The largest trade Enterprise's ever made was buying 2,000,000 units of Zosano Pharma Corp stock on 18 December 2017 worth over $10,000,000. On average, Enterprise trades about 1,461,305 units every 339 days since 2017. As of 26 November 2019 Enterprise still owns at least 4,270,691 units of Zosano Pharma Corp stock.
You can see the complete history of Enterprise L stock trades at the bottom of the page.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... et Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: